34.52
-0.60 (-1.71%)
| Previous Close | 35.12 |
| Open | 34.92 |
| Volume | 17,377,881 |
| Avg. Volume (3M) | 34,589,974 |
| Market Cap | 142,502,494,208 |
| Price / Earnings (TTM) | 31.10 |
| Price / Earnings (Forward) | 21.64 |
| Price / Sales | 6.45 |
| Price / Book | 2.84 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2026 |
| Profit Margin | 17.97% |
| Operating Margin (TTM) | 27.38% |
| Diluted EPS (TTM) | 0.850 |
| Quarterly Revenue Growth (YOY) | 18.30% |
| Quarterly Earnings Growth (YOY) | 63.90% |
| Total Debt/Equity (MRQ) | 10.86% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | 5.22 B |
| Levered Free Cash Flow (TTM) | -2.30 B |
| Return on Assets (TTM) | 5.05% |
| Return on Equity (TTM) | 8.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | WUXI BIO | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -1.00 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| WUXI BIO | 143 B | - | 31.10 | 2.84 |
| INNOVENT BIO | 146 B | - | 111.97 | 8.89 |
| SINO BIOPHARM | 117 B | 1.15% | 27.21 | 2.85 |
| AKESO | 104 B | - | - | 13.98 |
| PHARMARON | 54 B | 0.92% | 20.42 | 2.23 |
| BEONE MEDICINES | 296 B | - | 663.87 | 7.45 |
|
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Insiders | 13.07% |
| % Held by Institutions | 35.91% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |